Abstract
Resistance to cytotoxic chemotherapy is a frequent clinical problem in patients with cancer that leads to their ineffective treatment. Although important progress has been made in oncology in recent years, most tumors respond only temporarily to the current drugs.
Keywords
- Acute Myeloid Leukemia
- Multidrug Resistance
- Nucleotide Excision Repair
- Base Excision Repair
- Multidrug Resistance Protein
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Sirotnak FM, Moccio DM, Young CW. Increased accumulation of methotrexate by murine tumor cells in vitro in the presence of probenecid which is mediated by a preferential inhibition of efflux. Cancer Res. 1981; 41: 966–76.
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976; 455: 152–62.
Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the ß cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995; 268: 423–6.
Papadopoulou B, Roy G, Dey S, Rosen BP, Ouellette M. Contribution of the Leishmania P-glycoprotein-related gene ItpgpA to oxyanion resistance. J Biol Chem 1994; 269:11980–6.
Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Che-mother Pharmacol. 1997; 40 (Suppl): S3–S8.
Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986; 47: 381–9.
Willingham MC, Richerd ND, Cornwell MM, et al. Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. J Histochem Cytochem. 1987; 35: 1451–6.
Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 1987; 84: 3004–8.
Safa AR, Glover CJ, Meyers MB, Biedler JL, Felsted RL. Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J Biol Chem. 1986; 261: 6137–40.
Schlemmer SR, Yang CH, Sirotnak FM. Functional modulation of multidrug resistance-related P-glycoprotein by Ca(2+)-calmodulin. J Biol Chem. 1995; 270: 11040–2.
Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990; 38: 1277–87.
Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA. 1987; 84: 265–9.
Cordon-Cardo C, O’Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci USA. 1989; 86: 695–8.
Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997; 89: 3323–9.
Willman CL. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol. 1997; 34: 25–33.
Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta. 1996; 1288: F37–F54.
Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989; 81: 116–24.
Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical deletion of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol. 1990; 8: 689–704.
Chan HS, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991; 325: 1608–14.
Lai SL, Goldstein LJ, Gottesman MM, et al. MDR1 gene expression in lung cancer. J Natl Cancer Inst 1989; 81: 1144–50.
Savaraj N, Wu CJ, Xu R, et al. Multidrug-resistant gene expression in small-cell lung cancer. Am J Clin Oncol. 1997; 20: 398–403.
Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations. Cancer Res. 1996; 56: 3010–20.
Dalton WS, Crowley JJ, Salmon SS, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer. 1995; 75: 815–20.
Naito M, Tsuruo T. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother Pharmacol. 1997; 40 (Suppl): S20–S24.
Shrivastava P, Hanibuchi M, Yano S, Parajuli P, Tsuruo T, Sone S. Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil. Cancer Chemother Pharmacol. 1998; 42: 483–90.
Smith AJ, Mayer U, Schinkel AH, Borst P. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst. 1998; 90: 1161–6.
Wishart GC, Bissett D, Paul J, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol. 1994; 12: 1771–7.
Wagner RW. The state of the art in antisense research. Nat Med. 1995; 1: 1116–8.
Cucco C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res. 1996; 56: 4332–7.
Hanchett LA, Baker RM, Dolnick BJ. Subclonal heterogeneity of the multidrug resistance phenotype in a cell line expressing MDR1 RNA. Somat Cell Mol Genet. 1994; 20: 463–80.
Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992; 258: 1650–4.
Mirski SE, Gerlach JH, Cole SP. Multidrug resistance in a human small cell lung cancer cell line selected in Adriamycin®. Cancer Res. 1987; 47: 2594–8.
Krishnamachary N, Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 1993; 53: 3658–61.
Barrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH, Twentyman PR. A 190- kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst. 1994; 86: 110–7.
Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 1994; 54: 152–8.
Slapak CA, Fracasso PM, Martell RL, Toppmeyer DL, Lecerf JM, Levy SB. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Res. 1994; 54: 5607–13.
Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SP. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res. 1993; 53: 3221–5.
Tasaki Y, Nakagawa M, Ogata J, et al. Reversal by a dihydropyridine derivative of nonP-glycoprotein-mediated multidrug resistance in etoposide-resistant human prostatic cancer cell line. J Urol. 1995; 154: 1210–6.
Hasegawa S, Abe T, Naito S, et al. Expression of multidrug resistance-associated protein(MRP), MDR1, and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer. 1995; 71: 907–13.
Slapak CA, Mizunuma N, Kufe DW. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood. 1994; 84: 3113–21.
Cole SP, Sparks KE, Fraser K. et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994; 54: 5902–10.
Kool M, deHaas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997; 57: 3537–47.
Taniguchi K, Wada M, Kohno K, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996; 56: 4124–9.
Breuninger LM, Paul S, Gaughan K, et al. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995; 55: 5342–7.
Lautier D, Canitrot Y, Deeley RG, Cole SP. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol. 1996; 52: 967–77.
Zaman GJ, Flens MJ, vanLeusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA. 1994; 91: 8822–6.
Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J. Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997; 1326: 12–22.
Muller M, Meijer C, Zaman GJ, et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA. 1994; 91: 13033–7.
Evers R, Cnubben NH, Wijnholds J, van Deetmer L, van Bladeren PJ, Borst P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett. 1997; 419: 112–6.
Zaman GJ, Cnubben NH, van Bladeren PJ, Evers R, Borst P. Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. FEBS Lett. 1996; 391: 126–30.
Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994; 54: 4313–20.
Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 1998; 58: 5130–6.
Keppler D, Leier I, Jedlitschky G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem. 1997; 378: 787–91.
Kruh GD, Gaughan KT, Godwin A, Chan A. Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst. 1995; 87: 1256–8.
Zaman GJ, Versantvoort CH, Smit JJ, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 1993; 53: 1747–50.
Broxterman HJ, Giaccone G, Lankelma J. Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Curr Opin Oncol. 1995; 7: 532–40.
Berger W, Hauptmann E, Elbling L, Vefterlein M, Kokoschka EM, Micksche M. Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer. 1997; 71: 108–115.
Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med. 1996; 334: 231–8.
Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia. 1995; 9: 1661–6.
Elliott T. How does TAP associate with MHC class I molecules? Immunol Today. 1997; 18: 375–9.
Neefjes JJ, Momburg F, Hammerling GJ. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science. 1993; 261: 769–71.
Izquierdo MA, Neefjes JJ, Mathari AE, Flens MJ, Scheffer GL, Scheper RJ. Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. Br J Cancer. 1996; 74: 1961–7.
Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63: 1129–36.
Scheper RJ, Broxterman HJ, Scheffer GL, etal. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993; 53: 1475–9.
Chugani DC, Kedersha NL, Rome LH. Vault immunofluorescence in the brain: new insights regarding the origin of microglia. J Neurosci. 1991; 11: 256–68.
Chugani DC, Rome LH, Kedersha NL. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci. 1993; 106: 23–29.
Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol. 1996; 148: 877–87.
Izquierdo MA, Shoemaker RH, Flens MJ, et al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer. 1996; 65: 230–7.
Izquierdo MA, van der Zee AG, Vermorken JB, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst. 1995; 87: 1230–7.
den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/ lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood. 1998; 91: 2092–8.
Dingemans AM, van Ark-Ofte J, van der Valk P, et al. Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann Oncol. 1996; 7: 625–30.
Lash LH, Jones DP. Renal glutathione transport. Characteristics of the sodium-dependent system in the basal-lateral membrane. J Biol Chem 1984; 259: 14508–14.
Hinchman CA, Truong AT, Ballatori N. Hepatic uptake of intact glutathione S-conjugate, inhibition by organic anions, and sinusoidal catabolism. Am J Physiol. 1993; 265: G547–54.
Loe DW, Stewart RK, Massey TE, Deeley RG, Cole SP. ATP-dependent transport of aflatoxin B 1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol. 1997; 51: 1034–41.
Gupta V, Jani JP, Jacobs S, et al. Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine. Cancer Chemother Pharmacol. 1995; 36: 13–19.
Prezioso JA, FitzGerald GB, Wick MM. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. J Invest Dermatol. 1992; 99: 289–93.
O’Dwyer PJ, LaCreta F, Nash S, et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res. 1991; 51: 6059–65.
Lyttle MH, Hocker MD, Hui HC, et al. Isozyme-specific glutathione-S-transferase inhibitors: design and synthesis. J Med Chem. 1994; 37: 189–94.
Wang JC. DNA topoisomerases: why so many? J Biol Chem. 1991; 266: 6659–62.
Hwang J, Hwong CL. Cellular regulation of mammalian DNA topoisomerases. Adv Pharmacol. 1994; 29A: 167–89.
Kapoor R, Slade DL, Fujimori A, Pommier Y, Harker WG. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol Res. 1995; 7: 83–95.
Kaufmann SH, McLaughlin SJ, Kastan MB, Liu LF, Karp JE, Burke PJ. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res. 1991; 51: 3534–43.
Potmesil M, Hsiang YH, Liu LF, et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res. 1988; 48: 3537–43.
Sullivan DM, Latham MD, Ross WE. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res. 1987; 47: 3973–9.
Campain JA, Gottesman MM, Pastan I. A novel mutant topoisomerase II a present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry. 1994; 33: 11327–32.
Beck WT, Danks MK, Wolverton JS, et al. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv Pharmacol. 1994; 29B: 145–69.
Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 1995; 55: 1339–46.
Campain JA, Padmanabhan R, Hwang J, Gottesman MM, Pastan I. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. J Cell Physiol. 1993; 155: 414–25.
Ganapathi R, Constantinou A, Kamath N, Dubyak G, Grabowski D, Krivacic K. Rersistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Mol Pharmacol. 1996; 50: 243–8.
Ritke MK, Murray NR, Allan WP, Fields AP, Yalowich JC. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of ß II protein kinase C. Mol Pharmacol. 1995; 48: 798–805.
Henderson GB, Tsuji JM, Kumar HP. Transport of folate compounds by leukemic cells. Evidence for a single influx carrier for methotrexate, 5-methyltetrahydrofolate, and folate in CCRF-CEM human lymphoblasts. Biochem Pharmacol. 1987; 36: 3007–14.
Moscow JA, Gong M, He R, et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res. 1995; 55: 3790–4.
Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem. 1995; 270: 17468–75.
Stark GR, Debatisse M, Giulotto E, Wahl GM. Recent progress in understanding mechanisms of mammalian DNA amplification. Cell. 1989; 57: 901–8.
Matherly LH, Taub JW, Ravindranath Y, et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood. 1995; 85: 500–9.
Rhee MS, Wang Y, Nair MG, Galivan J. Acquisition of resistance to antifolates caused by enhanced y-glutamyl hydrolase activity. Cancer Res. 1993; 53: 2227–30.
Schweitzer BI, Dicker AP, Bertino JR. Dihydrofolate reductase as a therapeutic target. FASEB J. 1990; 4: 2441–52.
Domin BA, Mahony WB, Zimmerman TP. Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem Pharmacol. 1993; 46: 503–10.
Spears CP, Gustavsson BG, Berne M, Frosing R, Bernstein L, Hayes AA. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res. 1988; 48: 5894–900.
Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol. 1994; 12: 2035–42.
van der Wilt CL, Pinedo HM, de Jong M, Peters GJ. Effect of folate diastereoisomers on the binding of 5-fluoro-2′-deoxyuridine-5′-monophosphate to thymidylate synthase. Biochem Pharmacol. 1993; 45: 1177–9.
Bapat AR, Zarow C, Danenberg PV. Human leukemic cells resistant to 5-fluoro-2′-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. J Biol Chem. 1983; 258: 4130–6.
Jenh CH, Geyer PK, Baskin F, Johnson LF. Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. Mol Pharmacol. 1985; 28: 80–85.
Peters GJ, van Groeningen CJ. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol. 1991; 2: 469–80.
Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988; 6: 1653–64.
Sirotnak FM, Barrueco JR. Membrane transport and the antineoplastic action of nucleoside analogues. Cancer Metastas Rev. 1987; 6: 459–80.
Capizzi RL, Yang JL, Rathmell JP, et al. Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation. Semin Oncol. 1985; 12: 65–74.
Ross DD, Cuddy DP, Cohen N, Hensley DR. Mechanistic implications of alterations in HL-60 cell nascent DNA after exposure to 1–0-D-arabinofuranosylcytosine. Cancer Chemother Pharmacol. 1992; 31: 61–70.
Drenthe-Schonk AM, Holdrinet RS, van Egmond J, Wessels JM, Haanen C. Cytokinetic changes after cytosine arabinoside in acute non-lymphocyte leukemia. Leuk Res. 1981; 5: 89–96.
Flasshove M, Strumberg D, Ayscue L, et al. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia. 1994; 8: 780–5.
Fridland A, Verhoef V. Mechanism for ara-CTP catabolism in human leukemic cells and effect of deaminase inhibitors on this process. Semin Oncol. 1987; 14: 262–8.
Kreis W, Lesser M, Budman DR, et al. Phenotypic analysis of 1–0-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response. Cancer Chemother Pharmacol. 1992; 30: 126–30.
Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998; 24: 331–44.
Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990; 40: 2353–62.
Heiger-Bernays WJ, Essigmann JM, Lippard SJ. Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. Biochemistry 1990; 29: 8461–6.
Ewig RA, Kohn KW. DNA damage and repair in mouse leukemia L1210 cells treated with nitrogen mustard.1,3-bis(2-chloroethyl)-1-nitrosourea, and other nitrosoureas. Cancer Res. 1977; 37: 2114–22.
Sherman SE, Gibson D, Wang AH, Lippard SJ. X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]. Science. 1985; 230: 412–7.
Hartley JA, Gibson NW. DNA damage and cytotoxicity of 2-chloroethyl (methylsulfonyl)- methanesulfonate (NSC 338947) produced in human colon carcinoma cells with or without methylating agent pretreatment. Cancer Res. 1986; 46: 3871–5.
Hurley LH, Reynolds VL, Swenson DH, Petzold GL, Scahill TA. Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science. 1984; 226: 843–4.
Kohn KW. Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1 nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res. 1977; 37: 1450–4.
Bennett RA, Pegg AE. Alklylation of DNA in rat tissues following administration of streptozotocin. Cancer Res. 1981; 41: 2786–90.
Gonzaga PE, Brent TP. Affinity purification and characterization of human O6-alkylguanine-DNA alkyltransferase complexed with BCNU-treated, synthetic oligonucleotide. Nucleic Acids Res. 1989; 17: 6581–90.
Ludlum DB. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res. 1990; 233: 117–26.
Wu ZN, Chan CL, Eastman A, Bresnick E. Expression of human O6-methylguanine-DNA methyltransferase in a DNA excision repair-deficient Chinese hamster ovary cell line and its response to certain alkylating agents. Cancer Res. 1992; 52: 32–35.
Chae MY, McDougall MG, Dolan ME, Swenn K, Pegg AE, Moschel RC. Substituted O6- benzylguanine derivatives and their inactivation of human O6-alkylguanine-DNA alkyltransferase. J Med Chem. 1994; 37: 342–7.
Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA. 1990; 87: 5368–72.
McCormick JE, McElhinney RS. Nitrosoureas from chemist to physician: classification and recent approaches to drug design. Eur J Cancer. 1990; 26: 207–21.
Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 1990; 50: 6119–29.
Seeberg E, Eide L, Bjoras M. The base excision repair pathway. Trends Biochem Sci. 1995; 20: 391–7.
Frosina G, Fortini P, Rossi O, et al. Two pathways for base excision repair in mammalian cells. J Biol Chem. 1996; 271: 9573–8.
Klungland A, Lindahl T. Second pathway for completion of human DNA base excision- repair: reconstitution with purified proteins and requirement for DNase IV (FEN1). EMBO J. 1997; 16: 3341–8.
Sancar A, Sancar GB. DNA repair enzymes. Annu Rev Biochem. 1988; 57: 29–67.
Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer. 1993; 71: 1571–80.
Dabholkar M, Parker R, Reed E. Determinants of cisplatin sensitivity in non-malignant non-drug-selected human T cell lines. Mutat Res. 1992; 274: 45–56.
Dabholkar M, Bradshaw L, Parker RJ, et al. Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro. Environ Health Perspect. 1992; 98: 53–59.
Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992; 89: 3070–74.
Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest. 1991; 87: 772–777.
van Duin M, de Wit J, Odijk H, et al. Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell. 1986; 44: 913–23.
Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis. 1993; 14: 2177–80.
Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. 1994; 94: 703–8.
Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998; 16: 309–16.
Leveillard T, Andera L, Bissonnette N, et al. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J. 1996; 15: 1615–24.
Wang XW, Yeh H, Schaeffer L, et al. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet. 1995; 10: 188–95.
Wang XW, Vermeulen W, Coursen JD, et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 1996; 10: 1219–32.
Modrich P. Mismatch repair, genetic stability, and cancer. Science. 1994; 266: 1959–60.
Goldmacher VS, Cuzick RA Jr, Thilly WG. Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and Nmethyl-N′-nitro-N-nitrosoguanidine. J Biol Chem. 1986; 261: 12462–71.
Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and Adriamycin® resistance are associated with MutLá and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem. 1996; 271: 19645–8.
Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer. 1991; 64: 192–6.
Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994; 78: 539–42.
Quillet-Mary A, Mansat V, Duchayne E, et al. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia. 1996; 10: 417–25.
Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26: 239–57.
Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol. 1980; 68: 251–306.
Lane DP. p53 and human cancers.Br Med Bull. 1994; 50: 582–99.
Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 1979; 17: 43–52.
Resnick-Silverman L, St. Clair S, Maurer M, Zhao K, Manfredi JJ. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev 1998; 12:2102–7.
Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53- dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 1994; 8: 2540–51.
Linke SP, Clarkin KC, Wahl GM. p53 mediates permanent arrest over multiple cell cycles in response to y-irradiation. Cancer Res. 1997; 57: 1171–9.
Shivakumar CV, Brown DR, Deb S, Deb SP. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol. 1995; 15: 6785–93.
Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995; 92: 8493–7.
Stewart N, Hicks GG, Paraskevas F, Mowat M. Evidence for a second cell cycle block at G2/M by p53. Oncogene. 1995; 10: 109–15.
Attardi LD, Lowe SW, Brugarolas J, Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 1996; 15: 3693–3701.
Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 1994; 370: 220–3.
Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995; 80: 293–9.
Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994; 9: 1799–1805.
Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994; 54: 3131–5.
Chiou SK, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol. 1994; 14: 2556–63.
Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997; 389: 300–5.
Owen-Schaub LB, van Golen KL, Hill LL, Price JE. Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med. 1998; 188: 1717–23.
Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism ofp53-mediated apoptosis. Science. 1998; 282: 290–3.
Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991; 253: 49–53.
Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 1996; 13: 1971–81.
Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990; 335: 675–9.
Unger T, Nau MM, Segal S, Minna JD. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 1992; 11: 1383–90.
Demers GW, Halbert CL, Galloway DA. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology. 1994; 198: 169–74.
Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 10 protein. Nature. 1992; 357: 82–85.
Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993; 74: 957–67.
Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994; 266: 807–810.
Ju JF, Banerjee D, Lenz HJ, et al. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin Cancer Res. 1998; 4: 1315–22.
O’Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57:4285– 4300.
Weinstein JN, Myers TG, O’Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science. 1997; 275: 343–9.
Yang B, Eshleman JR, Berger NA, Markowitz SD. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res. 1996; 2: 1649–57.
Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol. 1996; 50: 1536–40.
Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996; 56: 892–8.
Vikhanskaya F, D’Incalci M, Broggini M. Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int J Cancer. 1995; 61: 397–401.
Trepel M, Scheding S, Groscurth P, et al. A new look at the role of p53 in leukemia cell sensitivity to chemotherapy. Leukemia. 1997; 11: 1842–9.
Debernardis D, Sire EG, De Feudis P, et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res. 1997; 57: 870–4.
Fan S, Cherney B, Reinhold W, Rucker K, O’Connor PM. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after Taxol or vincristine treatment. Clin Cancer Res. 1998; 4: 1047–54.
Wu GS, El-Diery WS. p53 and chemosensitivity. Nat Med. 1996; 2: 255–6.
Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med. 1996; 2: 72–79.
Cross SM, Sanchez CA, Morgan CA, et al. A p53-dependent mouse spindle checkpoint. Science. 1995; 267: 1353–6.
Bergh J, Norberg T, Sjoegren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995; 1: 1029–34.
Boku N, Chin K, Hosokawa K, et al. Biological markers as a predictor for response and prognosis of unrresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 1998; 4: 1469–74.
Brett MC, Pickard M, Green B, et al. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol. 1996; 22: 182–5.
Buttitta F, Marchetti A, Gadducci A, et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer. 1997; 75: 230–5.
Clahsen PC, van de Velde CJ, Duval C, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol. 1998; 16: 470–9.
Degeorges A, de Roquancourt A, Extra JM, et al. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res Treat. 1998; 47: 47–55.
Di Leo A, Bajetta E, Biganzoli L, et al. An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. Eur J Cancer. 1995; 31A: 2248–54.
Elledge RM, Gray R, Monsour E, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst. 1995; 87: 1254–6.
Jacquemier J, Penault-Llorca F, Viens P, et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res. 1994; 14: 2773–8.
Lenz HJ, Hayashi K, Salonga D, et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res. 1998; 4: 1243–50.
Linn SC, Pinedo HM, van Ark-Otte J, et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer. 1997; 71: 787–95.
Makris A, Powles TJ, Dowsett M, Allred C. p53 protein overexpression and chemosensitivity in breast cancer. Lancet 1995; 345: 1181–2.
Paradiso A, Rabinovich M, Vallejo C, et al. p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer. 1996; 69: 437–41.
Righetti SC, Delia-Torre TG, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996; 56: 689–93.
Rosell R, Gonzalez-Larriba JL, Alberola V, et al. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Semin Oncol. 1995; 22: 12–18.
Rusch V, Klimstra D, Venkatraman E, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995; 55: 5038–42.
Smith-Sorensen B, Kaern J, Holm R, Dorum A, Trope C, Borresen-Dale AL. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer. 1998; 78: 375–81.
Stal O, Stenmark-Askmalm M, Wingren S, et al. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol. 1995; 34: 767–70.
Renninson J, Baker BW, McGown AT, et al. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. Br J Cancer. 1994; 69: 609–12.
Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res. 1997; 3: 1195–1200.
Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997; 15: 2456–66.
Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA. 1986; 83: 5214–8.
Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol. 1990; 144: 3602–10.
Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988; 335: 440–2.
Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990; 348: 334–6.
Matsuzaki Y, Nakayama K, Nakayama K, et al. Role of bcl-2 in the development of lymphoid cells from the hematopoietic stem cell. Blood. 1997; 89: 853–862.
Uhlmann EJ, D’Sa-Eipper C, Subramanian T, Wagner AJ, Hay N, Chinnadurai G. Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation. Cancer Res. 1996; 56: 2506–9.
Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 1993; 53: 4701–14.
Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994; 124: 1–6.
Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am. 1995; 9: 451–73.
Strasser A, Huang DC, Vaux DL. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta. 1997; 1333: F151–78.
Allsopp TE, Wyatt S, Paterson HF, Davies AM. The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell. 1993; 73: 295–307.
Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997; 3: 614–20.
Brown R. The bcl-2 family of proteins. Br Med Bull. 1997; 53: 466–77.
Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996; 56: 1253–5.
Siegel RM, Katsumata M, Miyashita T, Louie DC, Greene MI, Reed JC. Inhibition of thymocyte apoptosis and negative antigenic selection of bcl-2 transgenic mice. Proc Natl Acad Sci USA. 1992; 89: 7003–7.
Kondo S, Yin D, Morimura T, Oda Y, Kikuchi H, Takeuchi J. Transfection with a bcl-2 expression vector protects transplanted bone marrow from chemotherapy-induced myelosuppresseion. Cancer Res. 1994; 54: 2928–33.
Offit K, Koduru PR, Hollis R, et al. 18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. Br J Haematol. 1989; 72: 178–83.
Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med. 1989; 320: 1047–54.
Pezzella F, Jones M, Ralfkiaer E, Ersboll J, Gatter KC, Mason DY. Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer. 1992; 65: 87–89.
Jacobson JO, Wilkes BM, Kwaiatkowski DJ, Medeiros LJ, Aisenberg AC, Harris NL. bcl-2 rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features. Cancer. 1993; 72: 231–6.
Piris MA, Pezzella F, Martinez-Montero JC, et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer. 1994; 69: 337–41.
Romaguera JE, Pugh W, Luthra R, Goodacre A, Cabanillas F. The clinical relevance of t(14;18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma. Ann Oncol. 1993; 4: 51–54.
Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas. Blood. 1997; 89: 601–9.
Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993; 81: 3091–6.
McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992; 52: 6940–4.
Takayama K, Ogata K, Nakanishi Y, Yatsunami J, Kawasaki M, Hara N. Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer. Cancer J Sci Am. 1996; 2: 212.
Bonetti A, Zaninelli M, Leone R, et al. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 1998; 4:2331– 2336.
van Slooten HJ, Clahsen PC, van Dierendonck JH, et al. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer. 1996; 74: 78–85.
Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature. 1992; 359: 423–6.
Oswald F, Lovec H, Moeroey T, Lipp M. E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Oncogene. 1994; 9: 2029–36.
Chiarugi V, Ruggiero M. Role of three cancer “master genes” p53, bc12 and c-myc on the apoptotic process. Tumori. 1996; 82: 205–9.
Reyt E, Lavieille JP, Brambilla E, Barra Y, Riva C. [Expression of oncogenes C-myc, C-and N-ras in advanced cancers of the upper respiratory and digestive tracts. Correlation with tumor clinical response to chemotherapy]. Ann Otolaryngol Chir Cervicofac. 1993; 110: 310–5.
Riva C, Lavieille JP, Reyt E, Brambilla E, Lunardi J, Brambilla C. Differential c-myc, cjun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Eur J Cancer B Oral Oncol. 1995; 31B: 384–91.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Tolis, C., Ferreira, C.G., Pinedo, H.M., Giaccone, G. (2000). Molecular Pathways of Drug Resistance. In: Bronchud, M.H., Foote, M.A., Peters, W.P., Robinson, M.O. (eds) Principles of Molecular Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-222-7_13
Download citation
DOI: https://doi.org/10.1007/978-1-59259-222-7_13
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-6274-7
Online ISBN: 978-1-59259-222-7
eBook Packages: Springer Book Archive